2019
DOI: 10.21518/2079-701x-2018-21-132-137
|View full text |Cite
|
Sign up to set email alerts
|

Dexansoprazole MV in the treatment of gastroesophageal reflux disease

Abstract: Dexlensoprazole MB is the R-enantiomer of lansoprazole and is currently the only proton pump inhibitor with the new Dual Delayed Release delivery technology. The pharmacokinetics of the drug shows two peaks of release in the 12-finger and small intestine; antisecretory effect is shown in doses of 30 mg, 60 mg, and retention of intragastric pH > 4 more than 16.5 hours per day; regardless of the time of administration. Clinical studies have shown that dexlansoprazole MB is highly effective in the healing of e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 32 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?